- Charles River Laboratories ( NYSE: CRL ) has expanded its cell therapy contract development and manufacturing facility in Memphis, Tenn.
- The company has added nine processing suites to the existing 16.
- The facility allows for the manufacture of clinical and commercial cell and gene-modified cell therapies.
- It previously received European Medicines Agency approval to commercially produce allogeneic cell therapy drug products.
- Read why Seeking Alpha contributor Seeking Profits has a sell rating on Charles River ( CRL ).
For further details see:
Charles River Laboratories expands cell therapy manufacturing capacity